Toxicology – Amoxapine and Loxapine

Core Concept

Amoxapine and loxapine are structurally related dibenzoxazepine drugs with important neurologic and cardiovascular toxicity in overdose.

• Amoxapine – tetracyclic antidepressant with pharmacologic similarities to tricyclic antidepressants (TCAs)
• Loxapine – antipsychotic, not an antidepressant

The most important manifestations of serious overdose are:

• CNS depression
• Seizures
• Tachycardia
• Hypotension
• Cardiac conduction abnormalities
• QRS widening or ventricular dysrhythmias in severe cases

A particularly important feature of amoxapine poisoning is its strong association with seizures, which can be recurrent or prolonged.

There is no specific antidote.

⸻

Pharmacology

Amoxapine and loxapine have complex receptor effects.

Amoxapine primarily inhibits neuronal reuptake of:

• Norepinephrine
• To a lesser extent, serotonin

It and its metabolites also have dopamine-receptor antagonist activity.

Loxapine acts primarily as an antipsychotic through:

• Dopamine D₂ antagonism
• Serotonin-receptor antagonism
• Additional adrenergic, histaminergic, and muscarinic effects

The older description that both drugs simply block reuptake of norepinephrine, serotonin, and dopamine is therefore an oversimplification.

⸻

Mechanisms of Toxicity

Several mechanisms may contribute:

CNS toxicity

Produces:

• Sedation
• Altered mental status
• Seizures
• Coma

Cardiac sodium-channel blockade

In substantial poisoning this can impair myocardial depolarization and produce:

• QRS widening
• Conduction delay
• Ventricular dysrhythmias
• Hypotension

α-Adrenergic blockade

Contributes to:

• Peripheral vasodilation
• Hypotension

Antimuscarinic effects

May contribute to:

• Tachycardia
• Altered mental status
• Reduced bowel motility
• Other antimuscarinic findings

⸻

Toxic Dose

There is no sufficiently reliable dose threshold to predict severity in an individual patient.

Historical fatal-dose reports should not be used as bedside treatment cutoffs.

Severity depends on:

• Drug
• Amount
• Patient size
• Coingestants
• Cardiovascular disease
• Seizure susceptibility
• Time to treatment

Clinical findings and ECG abnormalities are more important than the reported dose alone.

⸻

Neurologic Toxicity

Neurologic manifestations may develop abruptly.

Possible findings include:

• Drowsiness
• Confusion
• Agitation
• Lethargy
• Dysarthria
• Seizures
• Coma

Amoxapine is particularly notable because seizures may dominate the overdose syndrome even when severe cardiotoxicity is absent.

⸻

Seizures

Seizures can be:

• Recurrent
• Prolonged
• Difficult to control

Complications include:

• Hypoxemia
• Aspiration
• Hyperthermia
• Lactic acidosis
• Rhabdomyolysis
• Hyperkalemia
• Acute kidney injury
• Secondary brain injury

Therefore, rapid seizure control is one of the highest priorities.

⸻

Cardiovascular Toxicity

Possible manifestations include:

• Sinus tachycardia
• Hypotension
• QRS prolongation
• QT prolongation
• Conduction disturbances
• Ventricular ectopy
• Ventricular dysrhythmias

Serious cardiac toxicity is less consistently prominent than in classic severe TCA poisoning, particularly with amoxapine, but it remains possible.

⸻

ECG Importance

Obtain an ECG after a clinically important overdose.

Assess particularly for:

• QRS duration
• QT/QTc
• Heart rate and rhythm
• AV conduction
• Ventricular ectopy
• Other evidence of sodium-channel blockade

Continuous cardiac monitoring is appropriate for symptomatic or significant poisoning.

⸻

Sodium-Channel Blockade

If myocardial sodium channels are substantially inhibited:

Phase-0 depolarization slows → ventricular conduction slows → QRS widens

Increasing toxicity may then produce:

• Hypotension
• Ventricular dysrhythmias
• Cardiovascular collapse

This resembles the cardiotoxic mechanism of TCA poisoning.

⸻

Sodium Bicarbonate

Clinically important sodium-channel blockade is treated with sodium bicarbonate, particularly when there is:

• Significant QRS widening
• Ventricular dysrhythmia attributable to sodium-channel blockade
• Hypotension associated with conduction toxicity

Its beneficial mechanisms include:

• Sodium loading
• Serum alkalinization
• Reduction in drug binding to sodium channels

Therapy is guided by ECG and physiologic response rather than blindly pursuing an arbitrary bicarbonate dose.

⸻

QT Prolongation

QT prolongation may also occur.

Management includes:

• Continuous ECG monitoring
• Correction of potassium abnormalities
• Correction of magnesium abnormalities
• Removal of additional QT-prolonging drugs

If torsades de pointes develops, treatment follows standard toxicologic torsades management, including magnesium and electrical therapy when clinically required.

⸻

Hypotension

Hypotension may result from:

• α-Adrenergic blockade
• Myocardial sodium-channel blockade
• Dysrhythmia
• Acidemia
• Prolonged seizures
• Sedative coingestants

Treatment should therefore address the underlying mechanism rather than assuming simple volume depletion.

⸻

Management of Hypotension

Initial treatment may include appropriate isotonic crystalloid when volume support is indicated.

Persistent shock may require vasopressor therapy.

Norepinephrine is generally favored for persistent vasodilatory hypotension in modern critical-care practice.

If sodium-channel blockade is contributing, sodium bicarbonate is also important.

The older routine sequence of Trendelenburg positioning followed by dopamine is outdated.

⸻

Pulmonary Complications

Severe poisoning can cause:

• Respiratory depression
• Loss of airway protective reflexes
• Aspiration pneumonitis
• Hypoxemia
• Acute lung injury

Airway management is particularly important when recurrent seizures or coma develop.

⸻

Hyperthermia

Hyperthermia may result from:

• Recurrent muscular activity during seizures
• Agitation
• Severe systemic toxicity

Marked hyperthermia increases the risk of:

• Rhabdomyolysis
• Renal injury
• Coagulopathy
• Multiorgan dysfunction

Temperature should therefore be monitored in severe poisoning.

⸻

Metabolic Acidosis

Prolonged seizures commonly produce lactic acidosis.

Acidemia is particularly concerning when sodium-channel-blocking drugs are involved because lower pH can worsen cardiotoxicity.

Management focuses on:

• Rapid seizure control
• Adequate ventilation and oxygenation
• Restoration of perfusion
• Sodium bicarbonate when sodium-channel cardiotoxicity is present

⸻

Rhabdomyolysis

Repeated seizures can cause substantial skeletal-muscle breakdown.

Possible consequences include:

• Elevated CK
• Hyperkalemia
• Myoglobinuria
• Acute kidney injury

Monitor:

• CK
• Potassium
• Creatinine
• Urine output

when prolonged or repeated seizures occur.

⸻

Renal Injury

Acute kidney injury is usually secondary rather than a direct defining effect.

Potential mechanisms include:

• Rhabdomyolysis
• Hypotension
• Dehydration
• Multiorgan toxicity

⸻

Serotonin Toxicity

Amoxapine has serotonergic activity, so serotonin toxicity is possible particularly with serotonergic coexposures.

However, not every overdose should be labeled serotonin syndrome.

Look for the characteristic syndrome of:

• Agitation
• Hyperreflexia
• Clonus
• Tremor
• Autonomic activation
• Hyperthermia in severe cases

Clonus and hyperreflexia help distinguish serotonin toxicity from nonspecific overdose-related agitation or seizures.

⸻

Loxapine and Extrapyramidal Effects

Because loxapine is a dopamine antagonist, therapeutic use or poisoning can potentially produce:

• Acute dystonia
• Akathisia
• Parkinsonian findings

These should be distinguished from seizure activity.

Severe hyperthermia and rigidity should also raise consideration of neuroleptic malignant syndrome, although acute overdose alone does not automatically imply NMS.

⸻

Diagnosis

Diagnosis is primarily clinical.

Important information includes:

• Exact drug
• Formulation
• Amount
• Time of ingestion
• Coingestants
• Seizure history
• Cardiovascular history

Serum amoxapine and loxapine concentrations are generally not useful for acute bedside management.

⸻

Essential Evaluation

Important early assessment includes:

• Airway and breathing
• Mental status
• Bedside glucose
• ECG
• Continuous cardiac monitoring in significant poisoning

Symptomatic patients may also require:

• Electrolytes
• Bicarbonate
• Creatinine
• Blood gas
• CK
• Urinalysis
• Lactate

⸻

Occult Coingestion

Intentional overdose frequently involves more than one substance.

Depending on circumstances, evaluate for important clinically silent coingestants, especially acetaminophen.

Salicylate testing may also be appropriate when the history or acid–base pattern warrants it.

⸻

Neuroimaging and Lumbar Puncture

Head CT, lumbar puncture, EEG, and infectious studies are not routine tests for a known uncomplicated overdose.

They become appropriate when:

• The diagnosis is uncertain
• Focal neurologic findings occur
• Trauma is possible
• CNS infection is suspected
• Seizures remain unexplained
• Mental status fails to improve as expected

⸻

Initial Management

Priorities are:

Airway/ventilation → seizure control → ECG assessment → circulation → temperature/metabolic complications

Patients with severe neurologic or cardiovascular toxicity require intensive monitoring.

⸻

Seizure Treatment

Benzodiazepines are first-line therapy for toxicant-induced seizures.

Persistent or recurrent seizures may require:

• Additional benzodiazepine therapy
• Phenobarbital
• Escalation to appropriate anesthetic/critical-care therapy for refractory status epilepticus

At the same time, clinicians should correct:

• Hypoglycemia
• Hypoxemia
• Major electrolyte abnormalities
• Hyperthermia

⸻

Phenytoin – Modern Correction

The historical source recommends phenytoin as an additional anticonvulsant.

Phenytoin is generally not preferred for toxin-induced seizures, because many toxic seizures do not result from the neuronal mechanisms that phenytoin treats effectively.

It is especially unattractive when the poisoning itself may cause sodium-channel cardiotoxicity.

⸻

Neuromuscular Blockade

Neuromuscular paralysis may occasionally be required for airway management or control of dangerous muscular activity in a critically ill patient.

However:

Paralysis does not terminate electrical seizure activity in the brain.

If a patient is paralyzed during refractory seizures, adequate anticonvulsant/anesthetic treatment must continue and EEG monitoring may be necessary.

⸻

Physostigmine – Avoid

Physostigmine should generally be avoided when significant amoxapine or loxapine poisoning is suspected, particularly when there is:

• QRS widening
• Conduction abnormality
• Seizure risk
• Mixed/unknown ingestion

Increasing cholinergic activity in a patient with significant cardiotoxic or proconvulsant poisoning can be dangerous.

⸻

GI Decontamination

Do not induce vomiting.

Abrupt seizures and CNS depression create substantial aspiration risk.

The historical recommendation for routine gastric lavage is also obsolete.

⸻

Activated Charcoal

A single dose of activated charcoal may be considered after a substantial recent ingestion when:

• Presentation is sufficiently early
• The drug is likely to remain in the GI tract
• The airway is protected or reliably intact

Charcoal should never delay:

• Seizure treatment
• Airway stabilization
• Treatment of shock or dysrhythmia

Routine multiple-dose activated charcoal is not established for amoxapine or loxapine poisoning.

⸻

Extracorporeal Removal

Hemodialysis and hemoperfusion are not expected to provide meaningful toxin removal because these drugs have pharmacokinetic properties unfavorable for extracorporeal clearance.

Management remains primarily supportive.

⸻

Observation

The historical universal “normal ECG at 6 hours = discharge” rule should not be applied mechanically.

Observation depends on:

• Drug and formulation
• Estimated amount
• Symptoms
• Serial ECG findings
• Mental status
• Seizures
• Coingestants
• Clinical trajectory

Because severe neurologic toxicity may develop abruptly, significant intentional or uncertain ingestions require appropriate monitored observation.

⸻

Admission

ICU-level management is appropriate for patients with:

• Recurrent seizures
• Coma or substantial CNS depression
• Respiratory failure
• Significant QRS widening
• Ventricular dysrhythmia
• Persistent hypotension
• Severe hyperthermia
• Significant metabolic complications

⸻

Prognosis

Patients without severe seizures, cardiovascular toxicity, or secondary complications often recover with supportive care.

Poor prognostic features include:

• Refractory status epilepticus
• Prolonged hypoxemia
• Severe hyperthermia
• Persistent shock
• Serious ventricular dysrhythmia
• Severe rhabdomyolysis or multiorgan dysfunction

Permanent neurologic injury generally results from severe secondary insults such as prolonged seizures or hypoxia rather than from a simple mild exposure.

⸻

Pregnancy

The historical FDA pregnancy letter category is obsolete.

In severe poisoning during pregnancy, maternal stabilization is the priority.

Particularly important threats to both mother and fetus include:

• Seizures
• Hypoxemia
• Hypotension
• Hyperthermia
• Dysrhythmias

Necessary resuscitative and anticonvulsant treatment should not be withheld solely because of pregnancy.

⸻

Safeguarding

The older source’s rigid age cutoffs for abuse or intentional poisoning are outdated.

Pediatric poisoning should instead be assessed according to:

• Developmental ability
• Medication accessibility
• Circumstances
• Consistency of the history
• Recurrent unexplained poisoning
• Overall safeguarding concerns

Intentional self-poisoning requires appropriate safety assessment after medical stabilization.

⸻

Important Modernization of the Older Source

• Amoxapine is a tetracyclic antidepressant; loxapine is an antipsychotic.
• Their pharmacology is more complex than simple norepinephrine/serotonin/dopamine reuptake blockade.
• Amoxapine is particularly associated with recurrent and potentially severe seizures.
• Both can produce TCA-like sodium-channel cardiotoxicity in substantial poisoning.
• ECG evaluation should focus on QRS, QT, rhythm, and conduction.
• Sodium bicarbonate is important when clinically significant sodium-channel blockade develops.
• Benzodiazepines are first-line for seizures.
• Phenytoin is generally not preferred for toxicant-induced seizures.
• Neuromuscular paralysis does not treat cerebral seizure activity.
• Physostigmine should generally be avoided in significant poisoning with seizure or conduction risk.
• Trendelenburg positioning and routine dopamine-first treatment of shock are outdated.
• Ipecac and routine gastric lavage are obsolete.
• Activated charcoal has only a selective early role when the airway is safe.
• Routine multiple-dose charcoal is not established.
• Hemodialysis and hemoperfusion do not meaningfully enhance elimination.
• There is no specific antidote.
• Fixed 6-hour discharge rules should not replace individualized clinical and ECG assessment.

Key Points

• Amoxapine overdose → prominent seizure risk ± TCA-like cardiotoxicity.
• Loxapine overdose → CNS depression, seizures, hypotension, and possible conduction toxicity.
• Recurrent seizures can lead to hyperthermia, lactic acidosis, rhabdomyolysis, AKI, aspiration, and hypoxic injury.
• Obtain an ECG and monitor significant exposures continuously.
• QRS widening/ventricular sodium-channel toxicity → sodium bicarbonate therapy.
• Toxicant-induced seizures → benzodiazepines first-line.
• Avoid physostigmine when seizure or sodium-channel cardiotoxicity is possible.
• Do not induce vomiting or routinely perform gastric lavage.
• Dialysis does not meaningfully remove these drugs.
• No specific antidote exists.